BioCardia CardiAMP trial roll-in cohort shows +80 sec exercise tolerance, 82% fewer angina episodes at 6 months

BioCardia, Inc.

Open-label roll-in cohort (N not given) met primary endpoint; no treatment-emergent major adverse cardiac events.
Average exercise tolerance improved by 80 seconds at six-month follow-up vs. pre-treatment.
Angina episodes reduced by an average of 82% at the six-month primary endpoint.
60% of patients showed substantial improvement in both exercise tolerance and angina reduction.
Results compare favorably to FDA-approved therapies Ranolazine and EECP; data to be submitted for peer review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.